Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Naproxen | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | | Naproxen | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Naproxen | hsa00480 | Glutathione metabolism | 3.29E-04 | 4 | Q9UJ14, Q16772, P09211, P30041 | GGTL3, GSTA3, GSTP1, PRDX6 | More | | Naproxen | hsa00500 | Starch and sucrose metabolism | 2.15E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Naproxen | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Naproxen | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Naproxen | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | | Naproxen | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Naproxen | hsa00970 | Aminoacyl-tRNA biosynthesis | 5.30E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Naproxen | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Naproxen | hsa00982 | Drug metabolism - cytochrome P450 | 1.06E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Naproxen | hsa00983 | Drug metabolism - other enzymes | 1.72E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Naproxen | hsa01100 | Metabolic pathways | 8.43E-03 | 11 | P35790, Q16772, P09211, Q9UJ14, P30041, P40926, Q7KZN9, P15121, Q9UHK6, Q86VZ5, Q9BQB6 | CHKA, GSTA3, GSTP1, GGTL3, PRDX6, MDH2, COX15, AKR1B1, AMACR, SGMS1, VKORC1 | More | | Naproxen | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | | Naproxen | hsa01524 | Platinum drug resistance | 4.44E-02 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Naproxen | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Naproxen | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | Naproxen | hsa03013 | RNA transport | 2.35E-05 | 10 | O14980, P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF4A2, EIF4B, TACC3 | More | | Naproxen | hsa03040 | Spliceosome | 5.67E-07 | 16 | O43143, O60508, P17844, P08579, P26368, P51991, P61978, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, DDX5, SNRPB2, U2AF2, HNRPA3, HNRPK, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Naproxen | hsa03410 | Base excision repair | 7.59E-03 | 1 | P27695 | APEX1 | More | | Naproxen | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Naproxen | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | Naproxen | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 3.53E-03 | 8 | P09341, P19875, P25024, P25025, P47992, Q9UBD3, P14784, P01375 | CXCL1, CXCL2, CXCR1, CXCR2, XCL1, XCL2, IL2RB, TNF | More | | Naproxen | hsa04062 | Chemokine signaling pathway | 5.65E-04 | 14 | P25024, P25025, P09341, P19875, P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | Naproxen | hsa04064 | NF-kappa B signaling pathway | 2.98E-04 | 13 | P10415, O00463, P14778, P19174, Q04759, Q9UDY8, Q16548, P06239, Q13315, P24522, P09341, P19875, Q06643 | BCL2, TRAF5, IL1R1, PLCG1, PRKCQ, MALT1, BCL2A1, LCK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | Naproxen | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | | Naproxen | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Naproxen | hsa04080 | Neuroactive ligand-receptor interaction | 3.81E-04 | 11 | P08311, Q15722, P21453, Q9H228, P43657, O00398, P21462, P21730, P14416, P07550, P35318 | CTSG, LTB4R, S1PR1, EDG8, P2RY5, P2RY10, FPR1, C5AR1, DRD2, ADRB2, ADM | More | | Naproxen | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Naproxen | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | | Naproxen | hsa04141 | Protein processing in endoplasmic reticulum | 1.91E-03 | 6 | P18848, Q15437, Q99941, P11142, P07900, Q9NR31 | ATF4, SEC23B, CREBL1, HSPA8, HSP90AA1, SAR1A | More | | Naproxen | hsa04145 | Phagosome | 4.48E-02 | 5 | Q15080, P05164, O60603, P35443, P13765 | NCF4, MPO, TLR2, THBS4, HLA-DOB | More | | Naproxen | hsa04151 | PI3K-Akt signaling pathway | 1.19E-03 | 19 | P62753, P42338, P43657, P27348, P20827, P49767, P07900, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P22105, P14784, Q99941, P18848, O00141, P30281 | RPS6, PIK3CB, P2RY5, YWHAQ, EFNA1, VEGFC, HSP90AA1, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, TNXB, IL2RB, CREBL1, ATF4, SGK, CCND3 | More | | Naproxen | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | | Naproxen | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Naproxen | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Naproxen | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.46E-02 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | Naproxen | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | | Naproxen | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Naproxen | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Naproxen | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Naproxen | hsa04612 | Antigen processing and presentation | 1.35E-03 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Naproxen | hsa04613 | Neutrophil extracellular trap formation | 2.06E-03 | 13 | O60603, P05164, P08246, Q9UM07, Q13547, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Naproxen | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Naproxen | hsa04650 | Natural killer cell mediated cytotoxicity | 8.31E-06 | 12 | P19174, P01375, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, P26715 | PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | | Naproxen | hsa04657 | IL-17 signaling pathway | 2.19E-02 | 6 | O00463, Q16539, P49841, P09341, P14780, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, TNF | More | | Naproxen | hsa04658 | Th1 and Th2 cell differentiation | 7.66E-07 | 12 | Q04759, P07766, P20963, P09693, P19174, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Naproxen | hsa04659 | Th17 cell differentiation | 5.84E-06 | 14 | Q04759, P19174, P06239, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P08238, P07766, P09693, P20963 | PRKCQ, PLCG1, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | | Naproxen | hsa04660 | T cell receptor signaling pathway | 1.09E-04 | 12 | Q9UDY8, Q04759, P42338, P10747, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239 | MALT1, PRKCQ, PIK3CB, CD28, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK | More | | Naproxen | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Naproxen | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Naproxen | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | | Naproxen | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | Naproxen | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | | Naproxen | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Naproxen | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | Naproxen | hsa04912 | GnRH signaling pathway | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | Naproxen | hsa04915 | Estrogen signaling pathway | 2.75E-03 | 5 | Q99941, P18848, P51828, P07900, P11142 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | | Naproxen | hsa04918 | Thyroid hormone synthesis | 1.69E-03 | 4 | P51828, Q99941, P18848, P02768 | ADCY7, CREBL1, ATF4, ALB | More | | Naproxen | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | | Naproxen | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Naproxen | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | | Naproxen | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | Naproxen | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Naproxen | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Naproxen | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.09E-03 | 7 | Q14643, P51828, P22694, P23771, Q99941, P18848, P10415 | ITPR1, ADCY7, PRKACB, GATA3, CREBL1, ATF4, BCL2 | More | | Naproxen | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.21E-02 | 5 | P84022, Q13485, P42338, P49767, P19174 | SMAD3, SMAD4, PIK3CB, VEGFC, PLCG1 | More | | Naproxen | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | Naproxen | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Naproxen | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Naproxen | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Naproxen | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Naproxen | hsa04976 | Bile secretion | 3.87E-02 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Naproxen | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Naproxen | hsa05031 | Amphetamine addiction | 6.41E-03 | 3 | Q13557, Q99941, P18848 | CAMK2D, CREBL1, ATF4 | More | | Naproxen | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.46E-04 | 6 | Q16539, P09341, P19875, P19174, P25024, P25025 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Naproxen | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Naproxen | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Naproxen | hsa05140 | Leishmaniasis | 4.59E-02 | 5 | O75015, O60603, P01375, Q16539, Q15080 | FCGR3B, TLR2, TNF, MAPK14, NCF4 | More | | Naproxen | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Naproxen | hsa05144 | Malaria | 2.98E-03 | 6 | P69905, P68871, O60603, P01375, P35443, P26718 | HBA2, HBB, TLR2, TNF, THBS4, KLRK1 | More | | Naproxen | hsa05146 | Amoebiasis | 7.10E-07 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Naproxen | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Naproxen | hsa05200 | Pathways in cancer | 9.46E-03 | 17 | Q13751, P42338, P08238, P19174, P43246, P84022, Q13485, Q13547, P30281, P49767, P43657, P63218, P50151, Q14344, Q7LDG7, O75293, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, MSH2, SMAD3, SMAD4, HDAC1, CCND3, VEGFC, P2RY5, GNG5, GNG10, GNA13, RASGRP2, GADD45B, IL2RB | More | | Naproxen | hsa05202 | Transcriptional misregulation in cancer | 2.90E-02 | 9 | Q12778, Q13315, P14780, Q16548, O15550, P05164, P08246, Q9C0K0, P24522 | FOXO1, ATM, MMP9, BCL2A1, UTX, MPO, ELA2, BCL11B, GADD45A | More | | Naproxen | hsa05203 | Viral carcinogenesis | 1.75E-03 | 7 | Q12933, Q99941, P18848, P42229, P27348, Q15283, P61978 | TRAF2, CREBL1, ATF4, STAT5A, YWHAQ, RASA2, HNRPK | More | | Naproxen | hsa05204 | Chemical carcinogenesis | 5.46E-03 | 2 | Q16772, P09211 | GSTA3, GSTP1 | More | | Naproxen | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | Naproxen | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Naproxen | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 6.79E-04 | 9 | P42338, P19174, P07766, P20963, P09693, P06239, O60603, P10747, Q04759 | PIK3CB, PLCG1, CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ | More | | Naproxen | hsa05321 | Inflammatory bowel disease | 1.17E-03 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | | Naproxen | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | | Naproxen | hsa05332 | Graft-versus-host disease | 3.45E-03 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | | Naproxen | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Naproxen | hsa05418 | Fluid shear stress and atherosclerosis | 4.81E-02 | 6 | Q16539, P10599, P14780, P01375, P14778, P27930 | MAPK14, TXN, MMP9, TNF, IL1R1, IL1R2 | More | | |